RedHill Biopharma Ltd. (2RH.F)
| Previous close | 0.9700 |
| Open | 0.7040 |
| Bid | 0.7380 x 70000 |
| Ask | 0.7940 x 70000 |
| Day's range | 0.7040 - 0.9580 |
| 52-week range | 0.5900 - 9.2000 |
| Volume | |
| Avg. volume | 2,399 |
| Market cap | 37.815M |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9970 |
| Earnings date | 24 Aug 2022 - 29 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.44 |
- PR Newswire
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first quarter 2022 financial results and operational highlights, targeting positive cash from operations1 to start during H2/22 and recent implementation of a comprehensive cost reduction plan, expected to generate operational cost savings of approximately $50 million over the next 18 months.
- PR Newswire
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
- PR Newswire
RedHill Presents New Talicia® Data Analyses at DDW 2022
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the presentation of two new data analyses from the Talicia® H. pylori eradication clinical trials program at Digestive Diseases Week (DDW) 2022.
